These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 25809133

  • 1. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
    Müller T.
    Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
    [Abstract] [Full Text] [Related]

  • 2. Valbenazine for the treatment of tardive dyskinesia.
    Müller T.
    Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
    [Abstract] [Full Text] [Related]

  • 3. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N.
    Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
    [Abstract] [Full Text] [Related]

  • 4. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H, Henchcliffe C.
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N, Jankovic J.
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [Abstract] [Full Text] [Related]

  • 6. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
    Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV.
    N Engl J Med; 2017 Jun 29; 376(26):2503-2506. PubMed ID: 28489481
    [No Abstract] [Full Text] [Related]

  • 7. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.
    Am J Psychiatry; 2017 May 01; 174(5):476-484. PubMed ID: 28320223
    [Abstract] [Full Text] [Related]

  • 8. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN, Aggarwal S, Yonan C.
    J Comp Eff Res; 2018 Feb 01; 7(2):135-148. PubMed ID: 28965423
    [Abstract] [Full Text] [Related]

  • 9. Valbenazine for Tardive Dyskinesia.
    Freudenreich O, Remington G.
    Clin Schizophr Relat Psychoses; 2017 Feb 01; 11(2):113-119. PubMed ID: 28742396
    [Abstract] [Full Text] [Related]

  • 10. Valbenazine: First Global Approval.
    Kim ES.
    Drugs; 2017 Jul 01; 77(10):1123-1129. PubMed ID: 28578484
    [Abstract] [Full Text] [Related]

  • 11. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM, Nicewonder JA.
    J Pharm Pract; 2019 Aug 01; 32(4):450-457. PubMed ID: 29455579
    [Abstract] [Full Text] [Related]

  • 12. Valbenazine in the treatment of tardive dyskinesia.
    Witek N, Comella C.
    Neurodegener Dis Manag; 2019 Apr 01; 9(2):73-81. PubMed ID: 30724115
    [Abstract] [Full Text] [Related]

  • 13. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC, Hauser RA.
    Expert Opin Pharmacother; 2017 Aug 01; 18(12):1279-1287. PubMed ID: 28699794
    [Abstract] [Full Text] [Related]

  • 14. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M, Pigato G, Kane JM, Correll CU.
    Drug Des Devel Ther; 2018 Aug 01; 12():1215-1238. PubMed ID: 29795977
    [Abstract] [Full Text] [Related]

  • 15. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
    Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF.
    J Clin Psychiatry; 2017 Aug 01; 78(9):1344-1350. PubMed ID: 29141124
    [Abstract] [Full Text] [Related]

  • 16. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F, Luther K, Talreja O.
    Am J Health Syst Pharm; 2020 Jan 24; 77(3):167-174. PubMed ID: 31974564
    [Abstract] [Full Text] [Related]

  • 17. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
    Stacy M, Sajatovic M, Kane JM, Cutler AJ, Liang GS, O'Brien CF, Correll CU.
    Mov Disord; 2019 Aug 24; 34(8):1203-1209. PubMed ID: 31234240
    [Abstract] [Full Text] [Related]

  • 18. Tardive Dyskinesia: New Treatments Available.
    Limandri BJ.
    J Psychosoc Nurs Ment Health Serv; 2019 May 01; 57(5):11-14. PubMed ID: 31042295
    [Abstract] [Full Text] [Related]

  • 19. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L.
    Expert Rev Neurother; 2018 Apr 01; 18(4):323-332. PubMed ID: 29557243
    [Abstract] [Full Text] [Related]

  • 20. Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
    Khurram SK, Ames M, Muniz J.
    J Clin Psychopharmacol; 2018 Apr 01; 41(2):220-221. PubMed ID: 33587391
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.